Andrew X Zhu

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 12

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

Liver international : official journal of the International Association for the Study of the Liver

British journal of cancer

Massachusetts General Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Massachusetts General Hospital Jul 01 2000

United States

Physician :: Medicine

Publications

Andrew X Zhu, Farshid Dayyani, Chia-Jui Yen, Zhenggang Ren, Yuxian Bai, Zhiqiang Meng, Hongming Pan, Paul Dillon, Shivani K Mhatre, Vincent E Gaillard, Sairy Hernandez, Robin Kate Kelley, Bruno Sangro
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Qibiao Wu, Yuanli Zhen, Lei Shi, Phuong Vu, Patricia Greninger, Ramzi Adil, Joshua Merritt, Regina Egan, Meng-Ju Wu, Xunqin Yin, Cristina R Ferrone, Vikram Deshpande, Islam Baiev, Christopher J Pinto, Daniel E McLoughlin, Charlotte S Walmsley, James R Stone, John D Gordan, Andrew X Zhu, Dejan Juric, Lipika Goyal, Cyril H Benes, Nabeel Bardeesy
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer discovery 12 (5) (2022)
Josep M Llovet, Amit G Singal, Augusto Villanueva, Richard S Finn, Masatoshi Kudo, Peter Robert Galle, Masafumi Ikeda, Sophie Callies, Louise M McGrath, Chunxiao Wang, Paolo Abada, Ryan C Widau, Elena Gonzalez-Gugel, Andrew X Zhu
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)
Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H Palmer, Arndt Vogel, Julien Edeline, Stephane Cattan, Masatoshi Kudo, Ann-Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L Chan, Jennifer J Knox, Shukui Qin, Abby B Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S Finn, Andrew X Zhu
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (12) (2022)
Joseph W Franses, Andrew X Zhu
Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (13) (2022)
Bo Hu, Mincheng Yu, Xiaolu Ma, Jia-Lei Sun, Chenglong Liu, Chunyan Wang, Suiyi Wu, Pei-Yao Fu, Zhen Yang, Yungang He, Yuanyuan Zhu, Cheng Huang, Xin-Rong Yang, Yinghong Shi, Shuangjian Qiu, Huichuan Sun, Andrew X Zhu, Jian Zhou, Yang Xu, Di Zhu, Jia Fan
IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer discovery 12 (7) (2022)
Andrew X Zhu, Ryan David Nipp, Richard S Finn, Peter R Galle, Josep M Llovet, Jean-Frederic Blanc, Takuji Okusaka, Ian Chau, David Cella, Allicia Girvan, Jonathon Gable, Lee Bowman, Chunxiao Wang, Yanzhi Hsu, Paolo B Abada, Masatoshi Kudo
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO open 5 (4) (2021)
Andrew X Zhu, Richard S Finn, Yoon-Koo Kang, Chia-Jui Yen, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih-Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British journal of cancer 124 (8) (2021)
Stephen P Hack, Andrew X Zhu
Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert opinion on investigational drugs 30 (10) (2021)
Maria Reig, Peter Robert Galle, Masatoshi Kudo, Richard S Finn, Josep M Llovet, Andrea L Rosso, William R Schelman, Kun Liang, Chunxiao Wang, Ryan C Widau, Paolo Abada, Andrew X Zhu
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver international : official journal of the International Association for the Study of the Liver 41 (3) (2020)
Lipika Goyal, Cynthia A Sirard, Michael Schrag, Michael H Kagey, Jennifer R Eads, Stacey Stein, Anthony B El-Khoueiry, Gulam A Manji, Thomas A Abrams, Alok A Khorana, Rebecca Miksad, Devalingam Mahalingam, Andrew X Zhu, Dan G Duda
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)
Josep M Llovet, Augusto Villanueva, Jorge A Marrero, Myron Schwartz, Tim Meyer, Peter R Galle, Riccardo Lencioni, Tim F Greten, Masatoshi Kudo, Sumithra J Mandrekar, Andrew X Zhu, Richard S Finn, Lewis Rowland Roberts, null null
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology (Baltimore, Md.) (2020)

Andrew X Zhu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Andrew X Zhu